ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet
IDSA White Paper on developing narrow-spectrum antimicrobials + editorial by G. Drusano
What does an antibiotic cost to develop? What is it worth? How to afford it?
Lancet: 10-20-30 targets to address AMR by 2030
Assessing antibiotic value: DTR, fire extinguishers, and a view from Australia
NIAID workshop: What is a robust PK-PD package?
Modeling the value of an effective antibiotic — Megiddo et al.
UK to expand NHS Subscription Pilot! Consultation Period launches
FDA analysis of 40-years of antibacterial development: Dheman et al.
New pipeline analysis: Cancer projects were funded 17x more than antibacterials during 2011-2020
In Praise of Non-Inferiority
How hard (and how) to Pull? Net value of Pull via a Transferrable Exclusivity Extension (TEE)
Mirror Bacteria: An AMR threat of unprecedented magnitude
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet